Diagnosing breast lesions by fine needle aspiration cytology or core biopsy: which is better? Gary M. TsePuay-Hoon Tan Review 05 June 2010 Pages: 1 - 8
Systematic review of aromatase inhibitors in the first-line treatment for hormone sensitive advanced or metastatic breast cancer Rob RiemsmaC. A. ForbesJ. Kleijnen Review 10 June 2010 Pages: 9 - 24
The cognitive effects of chemotherapy in post-menopausal breast cancer patients: a controlled longitudinal study Felice A. TagerPaula S. McKinleyDawn L. Hershman Preclinical study 06 November 2009 Pages: 25 - 34
The fog hasn’t lifted on “chemobrain” yet: ongoing uncertainty regarding the effects of chemotherapy and breast cancer on cognition Janette VardyHaryana Dhillon Invited commentary 06 January 2010 Pages: 35 - 37
GM-CSF is one of the main breast tumor-derived soluble factors involved in the differentiation of CD11b-Gr1- bone marrow progenitor cells into myeloid-derived suppressor cells Johanna K. MoralesMaciej KmieciakMasoud H. Manjili Preclinical study 08 November 2009 Pages: 39 - 49
GPR30 and estrogen receptor expression: new insights into hormone dependence of inflammatory breast cancer Hugo Arias-PulidoMelanie RoyceMassimo Cristofanilli Preclinical Study 10 November 2009 Pages: 51 - 58
Gli1 promotes cell survival and is predictive of a poor outcome in ERα-negative breast cancer Lusheng XuYeon-Jin KwonAndra R. Frost Preclinical Study 10 November 2009 Pages: 59 - 71
A unique proteolytic fragment of alpha1-antitrypsin is elevated in ductal fluid of breast cancer patient Junma ZhouBruce TrockJinong Li Preclinical study 10 November 2009 Pages: 73 - 86
Role of GPR30 in the mechanisms of tamoxifen resistance in breast cancer MCF-7 cells Atanas IgnatovTanja IgnatovThomas Kalinski Preclinical study 13 November 2009 Pages: 87 - 96
Prognostic impact of ALDH1 in breast cancer: a story of stem cells and tumor microenvironment Erika ResetkovaJorge S. Reis-FilhoSunil Badve Preclinical study 13 November 2009 Pages: 97 - 108
Is ALDH1 a good method for definition of breast cancer stem cells? Veronique NeumeisterDavid Rimm Invited Commentary 28 November 2009 Pages: 109 - 111
Cyclin D1 is a direct target of JAG1-mediated Notch signaling in breast cancer Brenda CohenMamiko ShimizuMichael Reedijk Preclinical Study 14 November 2009 Pages: 113 - 124
Concordant HER2 status between metastatic breast cancer cells in CSF and primary breast cancer tissue In Hae ParkYoungmee KwonJungsil Ro Preclinical study 15 November 2009 Pages: 125 - 128
Concordance of HER2 in primary tumor and leptomeningeal metastases: now what? Nancy U. Lin Invited Commentary 07 January 2010 Pages: 129 - 131
Five common single nucleotide polymorphisms in the PALB2 gene and susceptibility to breast cancer in eastern Chinese population A-Yong CaoKe-Da YuZhi-Ming Shao Preclinical study 18 November 2009 Pages: 133 - 138
Reciprocal regulation of ZEB1 and AR in triple negative breast cancer cells Tisheeka R. GrahamRami YacoubRuth M. O’Regan Preclinical Study 18 November 2009 Pages: 139 - 147
Molecular predictors of efficacy of adjuvant weekly paclitaxel in early breast cancer Miguel MartínÁlvaro Rodríguez-LescureEnrique de Álava Clinical trial 27 December 2009 Pages: 149 - 157
Adjuvant chemotherapy is not for everyone I. Craig Henderson Invited Commentary 12 June 2010 Pages: 159 - 162
CEF is superior to CMF for tumours with TOP2A aberrations: a Subpopulation Treatment Effect Pattern Plot (STEPP) analysis on Danish Breast Cancer Cooperative Group Study 89D Katrín Á. GunnarsdóttirMaj-Britt JensenBent Ejlertsen Clinical trial 13 May 2010 Pages: 163 - 169
Re-searching anthracycline therapy Catherine OakmanErica MorettiAngelo Di Leo Invited Commentary 15 June 2010 Pages: 171 - 175
Triple negative breast cancer in Korea-distinct biology with different impact of prognostic factors on survival Jung Ah LeeKwan-Il KimThe Korean Breast Cancer Society Clinical trial 24 June 2010 Pages: 177 - 187
DNA repair signature is associated with anthracycline response in triple negative breast cancer patients A. A. RodriguezA. MakrisJ. C. Chang Clinical trial 26 June 2010 Pages: 189 - 196
Weekly paclitaxel improved pathologic response of primary chemotherapy compared with standard 3 weeks schedule in primary breast cancer Meng QiJin Feng LiTao Ouyang Clinical trial 26 June 2010 Pages: 197 - 202
Associations between XPD polymorphisms and risk of breast cancer: a meta-analysis Zheng JiangChunxiang LiXishan Wang Epidemiology 29 January 2010 Pages: 203 - 212
Methionine synthase A2756G polymorphism and breast cancer risk: a meta-analysis involving 18,953 subjects Meiping LuFeng WangJinrong Qiu Epidemiology 29 January 2010 Pages: 213 - 217
XRCC2 Arg188His polymorphism is not directly associated with breast cancer risk: evidence from 37,369 subjects Ke-Da YuAo-Xiang ChenZhi-Ming Shao Epidemiology 02 February 2010 Pages: 219 - 225
The association between ERCC2 Asp312Asn polymorphism and breast cancer risk: a meta-analysis involving 22,766 subjects Lei YaoLi-Xin QiuLong Yu Epidemiology 02 February 2010 Pages: 227 - 231
Global breast cancer seasonality Eun-Young OhChristine AnsellWilliam J. M. Hrushesky Epidemiology 04 February 2010 Pages: 233 - 243
Mammographic density does not differ between unaffected BRCA1/2 mutation carriers and women at low-to-average risk of breast cancer Gretchen L. GierachJennifer T. LoudMark H. Greene Epidemiology 04 February 2010 Pages: 245 - 255
Population-based survival-cure analysis of ER-negative breast cancer Lan HuangKaren A. JohnsonEric J. Feuer Epidemiology 04 February 2010 Pages: 257 - 264
COMT Val158Met polymorphism and breast cancer risk: evidence from 26 case–control studies Haixia DingYuanyuan FuZhanwei Wang Epidemiology 04 February 2010 Pages: 265 - 270
Metformin and rapamycin have distinct effects on the AKT pathway and proliferation in breast cancer cells Mahvash ZakikhaniMarie-José BlouinMichael N. Pollak Brief Report 05 February 2010 Pages: 271 - 279
The use of FDG-PET in assessing axillary lymph node status in breast cancer: a systematic review and meta-analysis of the literature Rebecca PeareR. T. StaffS. D. Heys Brief Report 07 February 2010 Pages: 281 - 290
Comparative disease pattern of a patient with a novel BRCA2 truncation and knockout models for BRCA2 Josefa SalgadoCristina GutiérrezJesús García-Foncillas Brief Report 12 February 2010 Pages: 291 - 293
Treatment of breast cancer through the application of irreversible electroporation using a novel minimally invasive single needle electrode Robert E. Neal IIRavi SinghRafael V. Davalos Brief Report 27 February 2010 Pages: 295 - 301
Adjuvant!© Online estimation of chemotherapy effectiveness when added to ovarian function suppression plus tamoxifen for premenopausal women with estrogen-receptor-positive breast cancer Robert J. ParidaensShari GelberAron Goldhirsch Brief Report 27 February 2010 Pages: 303 - 310
Is there a role for ovarian function suppression in operable breast cancer? Joseph A. Sparano Invited Commentary 06 April 2010 Pages: 311 - 313
